Melatonin protects podocytes from angiotensin II-induced injury in an in vitro diabetic nephropathy model

Ji,Zhen‑Zhong; Xu,Yan‑Cheng

doi:10.3892/mmr.2016.5313

Melatonin protects podocytes from angiotensin II-induced injury in an in vitro diabetic nephropathy model

Authors:
- Zhen‑Zhong Ji
- Yan‑Cheng Xu
View Affiliations

Affiliations: Department of Integrated Wards, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: May 19, 2016 https://doi.org/10.3892/mmr.2016.5313
Pages: 920-926

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic nephropathy (DN) is a severe renal disorder characterized by podocyte damage and accumulation of extracellular matrix leading to further glomerulosclerosis, possibly via the activation of inflammatory signaling and the generation of oxidative stress. Melatonin has been considered a robust anti‑oxidant, and is able to attenuate DN in several animal models. In the present study, cell viability was examined by CCK-8 assay. Cell apoptosis, intracellular reactive oxygen species and mitochondrial membrane potential (MMP) levels were measured by flow cytometry. Western blot analysis was performed to detect the expression of Nephrin, B cell lymphoma‑2 (Bcl‑2)‑associated X protein (Bax), Bcl-2, Caspase-3, Janus kinase (JAK)2 and Signal transducer and activator of transcription (STAT)3 in podocytes. Based on an in vitro podocyte injury model, the present study found that the application of melatonin significantly reduced AngII‑induced apoptosis and increased the proliferative rate of cells, as evidenced by decreased expression levels of apoptotic proteins, including Caspase‑3 and Bax, and a change in the ratio of Bax/Bcl‑2. Further investigation demonstrated that a reduction in oxidative stress and the recovery of mitochondrial function were involved in this protective effect. In addition, the Jak/STAT signaling pathway was inhibited, indicating that cytokine‑mediated inflammation was also targeted by melatonin. The present study demonstrated for the first time, to the best our knowledge, that melatonin exerted an anti-apoptotic effect in AngII-mediated podocyte injury, and indicates a possible mechanism to explain the protective effect of melatonin in DN.

View Figures

View References

1	Adler S: Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol. 5:1165–1172. 1994.PubMed/NCBI
2	Mogensen CE, Christensen CK and Vittinghus E: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 32(Suppl 2): S64–S78. 1983. View Article : Google Scholar
3	Leehey DJ, Singh AK, Alavi N and Singh R: Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl. 77:S93–S98. 2000. View Article : Google Scholar : PubMed/NCBI
4	Lewis EJ, Hunsicker LG, Bain RP and Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 329:1456–1462. 1993. View Article : Google Scholar : PubMed/NCBI
5	Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z and Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:861–869. 2001. View Article : Google Scholar : PubMed/NCBI
6	Gross ML, El-Shakmak A, Szábó A, Koch A, Kuhlmann A, Münter K, Ritz E and Amann K: ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia. 46:856–868. 2003. View Article : Google Scholar : PubMed/NCBI
7	Somlo S and Mundel P: Getting a foothold in nephrotic syndrome. Nat Genet. 24:333–335. 2000. View Article : Google Scholar : PubMed/NCBI
8	Ma L and Fogo AB: Role of angiotensin II in glomerular injury. Semin Nephrol. 21:544–553. 2001. View Article : Google Scholar : PubMed/NCBI
9	Fogo AB: Renal fibrosis and the renin-angiotensin system. Adv Nephrol Necker Hosp. 31:69–87. 2001.PubMed/NCBI
10	Griendling KK and Ushio-Fukai M: Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept. 91:21–27. 2000. View Article : Google Scholar : PubMed/NCBI
11	Swaminathan S and Shah SV: Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease. Curr Opin Nephrol Hypertens. 17:143–148. 2008. View Article : Google Scholar : PubMed/NCBI
12	Hakim FA and Pflueger A: Role of oxidative stress in diabetic kidney disease. Med Sci Monit. 16:RA37–RA48. 2010.PubMed/NCBI
13	Ha H, Yu MR and Kim KH: Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radic Biol Med. 26:944–950. 1999. View Article : Google Scholar : PubMed/NCBI
14	Oktem F, Ozguner F, Yilmaz HR, Uz E and Dündar B: Melatonin reduces urinary excretion of N-acetyl-beta-D-glucosaminidase, albumin and renal oxidative markers in diabetic rats. Clin Exp Pharmacol Physiol. 33:95–101. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zhang H, Zhang HM, Wu LP, Tan DX, Kamat A, Li YQ, Katz MS, Abboud HE, Reiter RJ and Zhang BX: Impaired mitochondrial complex III and melatonin responsive reactive oxygen species generation in kidney mitochondria of db/db mice. J Pineal Res. 51:338–344. 2011. View Article : Google Scholar : PubMed/NCBI
16	Elbe H, Vardi N, Esrefoglu M, Ates B, Yologlu S and Taskapan C: Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats. Hum Exp Toxicol. 34:100–113. 2015. View Article : Google Scholar
17	Kim EY, Alvarez-Baron CP and Dryer SE: Canonical transient receptor potential channel (TRPC)3 and TRPC6 associate with large-conductance Ca2+-activated K+ (BKCa) channels: Role in BKCa trafficking to the surface of cultured podocytes. Mol Pharmacol. 75:466–477. 2009. View Article : Google Scholar
18	Lim AKh: Diabetic nephropathy-complications and treatment. Int J Nephrol Renovasc Dis. 7:361–381. 2014. View Article : Google Scholar :
19	Mundel P and Kriz W: Structure and function of podocytes: An update. Anat Embryol (Berl). 192:385–397. 1995. View Article : Google Scholar
20	Faul C, Asanuma K, Yanagida-Asanuma E, Kim K and Mundel P: Actin up: Regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol. 17:428–437. 2007. View Article : Google Scholar : PubMed/NCBI
21	Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P and Endlich K: Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol. 12:413–422. 2001.PubMed/NCBI
22	Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG and Shankland SJ: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 65:30–39. 2004. View Article : Google Scholar
23	Anwar MM and Meki AR: Oxidative stress in streptozotocin-induced diabetic rats: Effects of garlic oil and melatonin. Comp Biochem Physiol A Mol Integr Physiol. 135:539–547. 2003. View Article : Google Scholar : PubMed/NCBI
24	Lenz O, Elliot SJ and Stetler-Stevenson WG: Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol. 11:574–581. 2000.PubMed/NCBI
25	Gumustekin M, Tekmen I, Guneli E, Tugyan K, Topcu A, Ergonen AT, Ozdemir MH, Uysal N and Bediz CS: Short-term melatonin treatment improved diabetic nephropathy but did not affect hemorheological changes in diabetic rats. Pharmazie. 62:693–698. 2007.PubMed/NCBI
26	Ehrenberg B, Montana V, Wei MD, Wuskell JP and Loew LM: Membrane potential can be determined in individual cells from the nernstian distribution of cationic dyes. Biophys J. 53:785–794. 1988. View Article : Google Scholar : PubMed/NCBI
27	Nicholls DG and Ward MW: Mitochondrial membrane potential and neuronal glutamate excitotoxicity: Mortality and millivolts. Trends Neurosci. 23:166–174. 2000. View Article : Google Scholar : PubMed/NCBI
28	Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S and Danesh FR: Diabetic nephropathy: Mechanisms of renal disease progression. Exp Biol Med (Maywood). 233:4–11. 2008. View Article : Google Scholar
29	Scott JA and King GL: Oxidative stress and antioxidant treatment in diabetes. Ann N Y Acad Sci. 1031:204–213. 2004. View Article : Google Scholar
30	Brezniceanu ML, Liu F, Wei CC, Tran S, Sachetelli S, Zhang SL, Guo DF, Filep JG, Ingelfinger JR and Chan JS: Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int. 71:912–923. 2007. View Article : Google Scholar : PubMed/NCBI
31	Durvasula RV and Shankland SJ: Activation of a local renin angiotensin system in podocytes by glucose. Am J Physiol Renal Physiol. 294:F830–839. 2008. View Article : Google Scholar : PubMed/NCBI
32	Stitt-Cavanagh E, MacLeod L and Kennedy C: The podocyte in diabetic kidney disease. Scientific World Journal. 9:1127–1139. 2009. View Article : Google Scholar : PubMed/NCBI
33	Welsh GI and Saleem MA: Nephrin-signature molecule of the glomerular podocyte? J Pathol. 220:328–337. 2010.
34	Adams JM and Cory S: Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 26:61–66. 2001. View Article : Google Scholar : PubMed/NCBI
35	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
36	Aaronson DS and Horvath CM: A road map for those who don't know JAK-STAT. Science. 296:1653–1655. 2002. View Article : Google Scholar : PubMed/NCBI
37	Chuang PY and He JC: JAK/STAT signaling in renal diseases. Kidney Int. 78:231–234. 2010. View Article : Google Scholar : PubMed/NCBI
38	Quiroz Y, Ferrebuz A, Romero F, Vaziri ND and Rodriguez-Iturbe B: Melatonin ameliorates oxidative stress, inflammation, proteinuria and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol. 294:F336–F344. 2008. View Article : Google Scholar
39	Abkhezr M and Dryer SE: Angiotensin II and canonical transient receptor potential-6 activation stimulate release of a signal transducer and activator of transcription 3-activating factor from mouse podocytes. Mol Pharmacol. 86:150–158. 2014. View Article : Google Scholar : PubMed/NCBI